Angiotensin Receptors, Autoimmunity, and Preeclampsia

Yang Xia, Cissy Chenyi Zhou, Susan M. Ramin and Rodney E. Kellems

*J Immunol* 2007; 179:3391-3395; 
doi: 10.4049/jimmunol.179.6.3391
http://www.jimmunol.org/content/179/6/3391

---

**References**  This article cites 48 articles, 15 of which you can access for free at:
http://www.jimmunol.org/content/179/6/3391.full#ref-list-1

**Subscription**  Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

**Permissions**  Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts**  Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Angiotensin Receptors, Autoimmunity, and Preeclampsia

Yang Xia,2 * Cissy Chenyi Zhou,* Susan M. Ramin,† and Rodney E. Kellems*  

Preeclampsia is a pregnancy-induced hypertensive disorder that causes substantial maternal and fetal morbidity and mortality. Despite being a leading cause of maternal death and a major contributor to maternal and perinatal morbidity, the mechanisms responsible for the pathogenesis of preeclampsia are poorly understood. Recent studies indicate that women with preeclampsia have autoantibodies that activate the angiotensin receptor, AT1, and that autoantibody-mediated receptor activation contributes to pathophysiology associated with preeclampsia. The research reviewed here raises the intriguing possibility that preeclampsia may be a pregnancy-induced autoimmune disease. The Journal of Immunology, 2007, 179: 3391–3395.

Preeclampsia affects ~3–5% of all pregnancies. It is a multisystem disorder generally appearing after the 20th week of gestation and characterized by hypertension, proteinuria, vascular abnormalities, and often intrauterine growth retardation (1–3). Preeclampsia is a leading cause of maternal death and a major contributor to maternal and perinatal morbidity. The mechanisms responsible for the pathogenesis of preeclampsia are poorly understood. The only effective treatment is delivery of the fetus and placenta, often resulting in serious complications of prematurity for the neonate. Immune mechanisms have long been implicated in the pathogenesis of preeclampsia (4, 5). The results presented here provide additional support for this view by reviewing the evidence that women with preeclampsia have autoantibodies capable of activating the angiotensin AT1 receptor (6, 7). AT1 receptor agonistic Abs, herein termed AT1-AA, are rarely seen in normotensive pregnant women. Overall, these results raise the intriguing possibility that preeclampsia may be an autoimmune disease in which pathophysiological symptoms result from autoantibody-induced angiotensin receptor activation. These autoantibodies may represent novel therapeutic targets for preeclampsia.

Initial evidence for angiotensin receptor-activating autoantibodies in women with preeclampsia

The autoantibodies were originally detected by Wallukat et al. based on the ability to activate AT1 angiotensin receptors on cultured neonatal rat cardiac myocytes, resulting in increased cardiomyocyte contraction rates (6). They showed that AT1-AA increase the beating rate of the cultured cardiomyocytes, a feature that was blocked by AT1 receptor antagonists. Using affinity purification and peptide competition experiments, they showed that AT1-AA bind to a seven-amino acid sequence present on the second extracellular loop of the AT1 receptor. The presence of this peptide epitope, AFHYESQ, in the cardiomyocyte contraction assay blocked Ab-induced stimulation of cardiomyocyte contraction. These remarkable findings were the first to show that preeclamptic women possess stimulatory autoantibodies against the AT1 receptor and that these autoantibodies are directed to a common epitope associated with the second extracellular loop.

AT1-AA may contribute to multiple features of preeclampsia

In subsequent studies we showed (7, 8) that these autoantibodies activate AT1 receptors on human trophoblasts, resulting in increased synthesis and secretion of plasminogen activator inhibitor-1 (PAI-1). PAI-1 plays a role in trophoblast invasion by inhibiting the urokinase-type plasminogen activator, resulting in decreased conversion of plasminogen to plasmin, decreased extracellular matrix digestion, and shallow trophoblast invasion. We have also shown that AT1-AA activate AT1 receptors on cultured human mesangial cells resulting in the stimulation of PAI-1 synthesis and secretion, a feature that may contribute to kidney damage leading to proteinuria, a hallmark manifestation of preeclampsia (9). Increased PAI-1 production by trophoblast cells, mesangial cells, and possibly other cell types may contribute to the hypercoagulation sometimes associated with preeclampsia. Dechend et al. provided evidence that AT1-AA stimulate increased production of tissue factor by endothelial cells (10) and NADPH oxidase by vascular smooth muscle cells.
AT1-AA can function additively to induce sFlt-1 secretion through AT1 receptor activation. Our findings suggest that Ang II is a key regulator of sFlt-1 synthesis and secretion during normal pregnancy (14) and that the excessive accumulation of sFlt-1 observed in women with preeclampsia is due to the additional activation of AT1 receptors mediated by AT1-AA (Fig. 2).

**AT1-AA cross the placenta and enter the fetal circulation**

The transfer of Ig from the mother to the fetus through the placenta is a naturally occurring process by which the mother provides passive immunity to the developing fetus. Hence, the opportunity exists for AT1-AA to enter the fetal circulation.

FIGURE 2. Proposed model of Ang II- and AT1-AA-induced sFlt-1 secretion in normal pregnancy and in preeclampsia. The synthesis and secretion of sFlt-1 is increased late in a normal pregnancy through the action of Ang II (14). We have suggested that the antiangiogenic action of elevated sFlt-1 functions as a brake to inhibit continuing angiogenesis late in pregnancy (14). However, under preeclamptic conditions the additional activation of the AT1 receptor by the maternal circulating AT1-AA results in additional sFlt-1 secretion over that stimulated by Ang II alone. The excessive placenta-derived sFlt-1 has detrimental effects on placental development and maternal vascular and renal function. Our recent results (22) suggest that the excessive production of sFlt-1 can be prevented by the seven-amino acid epitope peptide and that this peptide may have therapeutic potential in the management of preeclampsia. 7-mer, Seven-amino acid epitope peptide.

FIGURE 3. A model to account for autoantibody induction during pregnancy. AT1-AA production is preceded by a maternal inflammatory response to placental ischemia. The decreased blood flow to the placenta in RUPP rats leads to placental ischemia and hypoxia. This may result in endovascular damage, leading to a maternal inflammatory response associated with the increased secretion of inflammatory cytokines (i.e., TNF-α and IL-6). The resulting inflammatory cytokine secretion contributes to AT1-AA production. AT1-AA will directly induce higher blood pressure and proteinuria via AT1 receptor activation. This eventually leads to more hypoxia, endovascular damage, and enhanced inflammatory response, further favoring autoantibody production.
Recent findings from Herse et al. provide preliminary evidence to support this expectation (20). Using the neonatal rat cardiomyocyte beating assay, they reported that the offspring of preeclamptic women with AT1-AA also contain the autoantibodies capable of activating the AT1 receptor. Infants born to normotensive pregnant women do not have AT1-AA. In agreement with these findings, we have observed AT1-AA in the cord blood of women with preeclampsia (C. Zhou, unpublished observations). AT1-AA was not observed in the cord blood of normotensive pregnant women. Overall, these studies indicate that AT1-AA cross the placenta and enter the fetal circulation. The presence of these biologically active autoantibodies may have detrimental effects on fetal growth and development.

### Detection of AT1-AA in pregnant women represents a potentially important preymptomatic risk factor

Important recent work by Walther et al. shows that AT1-AA can be detected before the 20th wk of gestation in women with impaired uterine perfusion by Doppler sonography (21). Using the cardiomyocyte contraction assay they found that AT1-AA were detected between the 18th and 22nd wk of gestation in women with reduced uterine perfusion. When followed to term, these women fell into three groups: those who developed preeclampsia, those characterized by fetuses with intrauterine growth retardation, and those with otherwise normal outcomes. AT1-AA was not observed in second-trimester women with a normal Doppler ultrasound. Thus, AT1-AA tracks women showing reduced uterine perfusion pressure during the second trimester and may serve to identify women at risk for intrauterine growth retardation and/or preeclampsia. The authors of this study suggested, as we had done earlier (7), that AT1-AA may be responsible for reduced trophoblast invasion and impaired placental development. The fact that AT1-AA can be detected many weeks before the symptoms of preeclampsia has significant implications regarding presymptomatic identification of women at risk for preeclampsia.

### Therapeutic possibilities based on blocking autoantibody-induced receptor activation

Currently there is no specific treatment for preeclampsia, and severe cases often require premature delivery of the infant. If maternal circulating AT1-AA contribute to the pathophysiology of preeclampsia, as suggested by the data reviewed here, then blocking the action of these autoantibodies may provide significant therapeutic benefit. One approach to this is based on in vitro studies showing that AT1-AA recognize a specific seven-amino acid sequence present on the second extracellular loop of the AT1 receptor (Fig. 1) and that the ability of AT1-AA to activate AT1 receptors on various cell types can be blocked by the presence of this heptapeptide epitope (6, 7). Our recent studies show that this peptide can neutralize AT1-AA in vivo and thereby prevent autoantibody-induced sFlt-1 production in pregnant mice (22). Thus, the use of epitope peptide therapy to block the action of angiotensin receptor-activating autoantibodies has the potential of being a safe and effective treatment of preeclampsia (Fig. 1).

#### Mechanism of Ab induced receptor activation

G protein-coupled receptors (GPCRs) were long considered to function as monomers. However, a large body of biochemical evidence published in recent years clearly indicates that GPCRs form homodimers, heterodimers, and possibly higher order oligomeric structures (23–25). Agonist-induced dimerization has been shown for a number of GPCRs, a feature that is consistent with recent evidence that GPCR dimers associate with a single heterotrimeric G protein complex. One of the best-studied GPCRs is the angiotensin receptor AT1. AbdAlla et al. have shown that the active form of the AT1 receptor is a homodimer and that homodimer formation is associated with enhanced Ang II responsiveness (26–28). Because AT1-AAs are bivalent, we propose that they exert their agonistic effect by cross-linking and thereby stabilizing AT1 receptor homodimers (Fig. 1). A thorough knowledge of the mechanism of Ab-induced receptor activation may provide insight that is useful in developing therapeutic strategies to block the action of the Abs, thereby reducing the detrimental effects of excessive AT1 receptor activation.

#### Placenta ischemia and hypoxia result in endovascular damage leading to a maternal inflammatory response; a possible foundation for autoantibody production in preeclampsia?

The etiology of autoimmune disease remains largely unknown. Multiple factors, including genetic predisposition, a maladaptive immune system, and environment challenge have been proposed to be involved in autoantibody production (29–31). Evidence presented below suggests that the generation of AT1-AA may be secondary to the reduced placental perfusion and increased maternal inflammatory response that is associated with preeclampsia.

It is a widely held view that the maternal syndrome of preeclampsia is secondary to placental abnormalities, especially those resulting from placental ischemia (1, 32). In this regard Granger and colleagues have developed a rat model of preeclampsia based on experimentally induced placental ischemia resulting from reduced uterine perfusion pressure (RUPP) (3, 33–35). Such experimentally manipulated pregnant rats developed hypertension, proteinuria, and other features of preeclampsia. Granger and colleagues also investigated the placentas and maternal circulation of rats with experimentally induced RUPP and found that TNF-α expression was elevated several fold (36). More recently, this group found that sera from

---

### Table 1. Examples of autoantibody-mediated receptor activation

<table>
<thead>
<tr>
<th>Receptor (Reference)</th>
<th>Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insulin receptor (42)</td>
<td>Hyperthyroidism (Grave’s disease)</td>
</tr>
<tr>
<td>β1-Adrenergic receptor (43)</td>
<td>Hypoglycemia</td>
</tr>
<tr>
<td>α1-Adrenergic receptor (47)</td>
<td>Dilated cardiomyopathy</td>
</tr>
<tr>
<td>Muscarinic M2 receptor (48)</td>
<td>Hypertension</td>
</tr>
<tr>
<td>Angiotensin AT-1 receptor (6–8)</td>
<td>Idiopathic dilated cardiomyopathy</td>
</tr>
<tr>
<td></td>
<td>Preeclampsia</td>
</tr>
</tbody>
</table>

---

The Journal of Immunology
RUPP-manipulated pregnant rats stimulated increased endothelin synthesis by endothelial cells through AT1 receptor activation (35). Additionally, in collaboration with the Berlin group, Granger and colleagues examined these rat models of preeclampsia for the presence of AT1-AA. Using the cardiomyocyte contraction bioassay, they observed AT1 receptor agonistic autoantibodies in RUPP pregnant rats but not in normal pregnant rats (37). They found that a low dose TNF-α infusion in pregnant rats also resulted in increased blood pressure and the appearance of AT1 receptor agonistic autoantibodies (34). Neither feature was induced by TNF-α infusion into nonpregnant rats, suggesting a role for pregnancy in the production of AT1-AA. These experimentally induced models of preeclampsia in the pregnant rat may provide a valuable model system to determine the immunological origins and pathophysiological role of AT1-AA in preeclampsia (Fig. 3).

**AT1-AA in malignant hypertension and renal allograft rejection.**

AT1 receptor-activating autoantibodies are not restricted to pregnancy. They have also been associated with other forms of hypertension (38, 39). More recently, AT1-AA were observed in kidney transplant recipients suffering from severe vascular rejection and malignant hypertension (40). Thus, these autoantibodies have appeared in multiple clinical circumstances associated with hypertension and vascular injury.

**Other examples of Ab-mediated receptor activation**

Autoantibodies capable of activating GPCRs have also been observed in other human diseases (Table I). One of the best known examples is Graves’ disease, a condition characterized by the presence of autoantibodies capable of activating the thyroid-stimulating hormone receptor on thyroid cells, resulting in the excessive production and secretion of thyroid hormones (41). Agonistic autoantibodies directed against the insulin receptor are associated with some forms of hypoglycemia (42). The autoantibodies directed against the cardiac β1-adrenergic receptor are associated with patients with dilated cardiomyopathy (43). These IgG Abs function as agonists for the β1-adrenergic receptor, resulting in a positive chronotropic effect on cultured cardiomyocytes. Jahns et al. used a rat model to provide direct evidence for a β1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy (44). In a follow-up paper this group showed that in humans these Abs are associated with increased cardiovascular mortality (45). Autoantibodies capable of activating the α1-adrenergic receptor are associated with various forms of hypertension (46, 47). Finally, autoantibodies capable of activating the muscarinic M2 receptor are associated with idiopathic dilated cardiomyopathy (48). Thus, the presence of agonistic autoantibodies directed against GPCRs has been observed in numerous disease states.

**Concluding remarks**

In 1999 Wallukat et al. reported their remarkable findings that sera from women with preeclampsia contain autoantibodies that react with AT1 receptors in a stimulatory fashion (6). Within a few years their important findings were confirmed and extended in numerous ways, showing that these autoantibodies activate AT1 receptors on cardiac myocytes, trophoblast cells, endothelial cells, mesangial cells, vascular smooth cells, and Chinese hamster ovary cells (Fig. 1). Altogether, these studies show that AT1-AA activate AT-1 receptors on a variety of cell types and provoke biological responses that are relevant to the pathophysiology of preeclampsia. We have recently shown that the introduction of these autoantibodies into pregnant mice resulted in the increased secretion of sFlt-1 (22) as well as other key features of preeclampsia, including hypertension and proteinuria (C. Zhou, unpublished observations). Available evidence indicates that the biological properties of these autoantibodies can be blocked by a seven-amino acid peptide that corresponds to a specific epitope associated with the second extracellular loop of the AT1 receptor. This fact has immediate therapeutic implications and also suggests a common immunological origin for these autoantibodies in different individuals. If AT1-AA play a significant role in the etiology and pathophysiology of preeclampsia, as we hypothesize, it may one day be possible to block this Ab response and thus either forestall or prevent the onset of preeclampsia.

**Disclosures**

The authors have no financial conflict of interest.

**References**


